廣告
香港股市 將收市，收市時間：29 分鐘

  • 恒指

    18,480.34
    -97.96 (-0.53%)
     

  • 國指

    6,530.09
    -42.36 (-0.64%)
     

  • 上證綜指

    3,147.74
    +7.02 (+0.22%)
     

  • 滬深300

    3,659.01
    +1.13 (+0.03%)
     

  • 美元

    7.8184
    +0.0006 (+0.01%)
     

  • 人民幣

    0.9223
    +0.0007 (+0.08%)
     

  • 道指

    38,852.27
    +176.59 (+0.46%)
     

  • 標普 500

    5,180.74
    +52.95 (+1.03%)
     

  • 納指

    16,349.25
    +192.92 (+1.19%)
     

  • 日圓

    0.0505
    -0.0001 (-0.20%)
     

  • 歐元

    8.4167
    -0.0014 (-0.02%)
     

  • 英鎊

    9.8010
    -0.0180 (-0.18%)
     

  • 紐約期油

    78.46
    -0.02 (-0.03%)
     

  • 金價

    2,328.20
    -3.00 (-0.13%)
     

  • Bitcoin

    63,762.95
    -686.84 (-1.07%)
     

  • CMC Crypto 200

    1,368.62
    +3.49 (+0.26%)
     

Best Momentum Stocks to Buy for January 31st

Zacks Equity Research
·2 分鐘文章

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:

ADMA Biologics, Inc. ADMA: This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.

ADMA Biologics Inc Price and Consensus

ADMA Biologics Inc Price and Consensus
ADMA Biologics Inc Price and Consensus

ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote

ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score  of A.

ADMA Biologics Inc Price

ADMA Biologics Inc Price
ADMA Biologics Inc Price

ADMA Biologics Inc price | ADMA Biologics Inc Quote

廣告

Ekso Bionics Holdings, Inc. EKSO: This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.

Ekso Bionics Holdings, Inc. Price and Consensus

Ekso Bionics Holdings, Inc. Price and Consensus
Ekso Bionics Holdings, Inc. Price and Consensus

Ekso Bionics Holdings, Inc. price-consensus-chart | Ekso Bionics Holdings, Inc. Quote

Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.

Ekso Bionics Holdings, Inc. Price

Ekso Bionics Holdings, Inc. Price
Ekso Bionics Holdings, Inc. Price

Ekso Bionics Holdings, Inc. price | Ekso Bionics Holdings, Inc. Quote

InhibikaseTherapeutics, Inc. IKT: This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.

Inhibikase Therapeutics, Inc. Price and Consensus

Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. Price and Consensus

Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote

Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.

Inhibikase Therapeutics, Inc. Price

Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. Price

Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote

 

See the full list of top ranked stocks here

 

Learn more about the Momentum score and how it is calculated here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ADMA Biologics Inc (ADMA) : Free Stock Analysis Report

Ekso Bionics Holdings, Inc. (EKSO) : Free Stock Analysis Report

Inhibikase Therapeutics, Inc. (IKT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research